Abstract
Background: It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth. The aim of this study was to examine the association of diabetes treatments with AAA growth in three patient cohorts. Methods: AAA growth was studied using ultrasound surveillance in cohort 1, repeated CT in cohort 2 and more detailed repeat CT in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. Results: A total of 1697 patients with an AAA were studied, of whom 118, 39 and 16 patients were prescribed metformin for the treatment of diabetes in cohorts 1, 2 and 3 respectively. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1: adjusted odds ratio (OR) 0·59, 95 per cent c.i. 0·39 to 0·87, P = 0·008; cohort 2: adjusted OR 0·38, 0·18 to 0·80, P = 0·011; cohort 3: adjusted OR 0·13, 0·03 to 0·61, P = 0·010). No other diabetes treatment was significantly associated with AAA growth in any cohort. Conclusion: These findings suggest a potential role for metformin in limiting AAA growth.
| Original language | English |
|---|---|
| Pages (from-to) | 1486-1493 |
| Number of pages | 8 |
| Journal | British Journal of Surgery |
| Volume | 104 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 1 Oct 2017 |
Fingerprint
Cite this
}
Association between metformin prescription and growth rates of abdominal aortic aneurysms. / Golledge, J.; Moxon, J.; Pinchbeck, J.; Anderson, G.; Rowbotham, S.; Jenkins, J.; Bourke, M.; Bourke, B.; Dear, A.; Buckenham, T.; Jones, R.; Norman, P. E.
In: British Journal of Surgery, Vol. 104, No. 11, 01.10.2017, p. 1486-1493.Research output: Contribution to journal › Article
TY - JOUR
T1 - Association between metformin prescription and growth rates of abdominal aortic aneurysms
AU - Golledge, J.
AU - Moxon, J.
AU - Pinchbeck, J.
AU - Anderson, G.
AU - Rowbotham, S.
AU - Jenkins, J.
AU - Bourke, M.
AU - Bourke, B.
AU - Dear, A.
AU - Buckenham, T.
AU - Jones, R.
AU - Norman, P. E.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Background: It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth. The aim of this study was to examine the association of diabetes treatments with AAA growth in three patient cohorts. Methods: AAA growth was studied using ultrasound surveillance in cohort 1, repeated CT in cohort 2 and more detailed repeat CT in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. Results: A total of 1697 patients with an AAA were studied, of whom 118, 39 and 16 patients were prescribed metformin for the treatment of diabetes in cohorts 1, 2 and 3 respectively. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1: adjusted odds ratio (OR) 0·59, 95 per cent c.i. 0·39 to 0·87, P = 0·008; cohort 2: adjusted OR 0·38, 0·18 to 0·80, P = 0·011; cohort 3: adjusted OR 0·13, 0·03 to 0·61, P = 0·010). No other diabetes treatment was significantly associated with AAA growth in any cohort. Conclusion: These findings suggest a potential role for metformin in limiting AAA growth.
AB - Background: It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth. The aim of this study was to examine the association of diabetes treatments with AAA growth in three patient cohorts. Methods: AAA growth was studied using ultrasound surveillance in cohort 1, repeated CT in cohort 2 and more detailed repeat CT in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. Results: A total of 1697 patients with an AAA were studied, of whom 118, 39 and 16 patients were prescribed metformin for the treatment of diabetes in cohorts 1, 2 and 3 respectively. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1: adjusted odds ratio (OR) 0·59, 95 per cent c.i. 0·39 to 0·87, P = 0·008; cohort 2: adjusted OR 0·38, 0·18 to 0·80, P = 0·011; cohort 3: adjusted OR 0·13, 0·03 to 0·61, P = 0·010). No other diabetes treatment was significantly associated with AAA growth in any cohort. Conclusion: These findings suggest a potential role for metformin in limiting AAA growth.
UR - http://www.scopus.com/inward/record.url?scp=85021375462&partnerID=8YFLogxK
U2 - 10.1002/bjs.10587
DO - 10.1002/bjs.10587
M3 - Article
VL - 104
SP - 1486
EP - 1493
JO - British Journal of Surgery
JF - British Journal of Surgery
SN - 0007-1323
IS - 11
ER -